drugset

Drugs / 10E8.4/iMab

Follow last change Apr 2026 re-read 9 days ago

10E8.4/iMab

Developed for: HIV infectious disease
Investigated by: David Ho · Henry M. Jackson Foundation for the Advancement of Military Medicine · National Institute of Allergy and Infectious Diseases (NIAID) · US Military HIV Research Program

Trials 1

today NCT05890963 · Ph 1

202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT05890963	Nov 2023 → Apr 2026 overdue	HIV infectious disease	David Ho	Active not recruiting	No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	10E8.4/iMab	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05890963 ↗
Route	Intramuscular	“10E8.4/iMab will be administered IV at the 600mg or 1800mg dose or IM at 600mg dose to participants in Step 1 per the Schedule of Events (SOE) based on the arm the participant...” NCT05890963 ↗
Route	Intravenous	“10E8.4/iMab will be administered IV at the 600mg or 1800mg dose or IM at 600mg dose to participants in Step 1 per the Schedule of Events (SOE) based on the arm the participant...” NCT05890963 ↗